Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hanmi, Spectrum Look For Differentiation As Poziotinib Progresses

This article was originally published in PharmAsia News

Executive Summary

South Korea's Hanmi Pharmaceutical and its global partner Spectrum Pharmaceuticals are moving closer to the commercialization of the oral pan-HER inhibitor poziotinib in the US with the submission by the US biotech of a Phase II breast cancer protocol to the FDA as part of an IND application. But the partners are having to fine-tune their development strategy given what is a crowded sector.


Related Content

Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC
Spectrum Failed To Heed FDA Advice On Apaziquone, And Is Paying The Price


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts